Veracyte, Inc. (VCYT) stock analysis

In our weekly check, Veracyte, Inc. is graded B (A to F). Of 22 checks on debt, profit, cash flow and trend: 17 pass, warnings: 2, red flags: 3.

Sector: Healthcare · Biotechnology

Strengths

• Low debt
• Margins rising
• Profits backed by cash
• High margins
• Strong free cash flow

Warning signs

• Very volatile
• High beta
• Low return on capital

Next earnings report: 2026-11-03

Similar companies

CDNA · BLLN · SHC · RDNT · GRAL · WGS

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-10

Open the full analysis